Trials / Terminated
TerminatedNCT00866333
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Syndax Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of entinostat, SNDX-275, in patients with relapsed or refractory Hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entinostat | Entinostat tablets |
Timeline
- Start date
- 2009-04-13
- Primary completion
- 2013-02-08
- Completion
- 2013-02-08
- First posted
- 2009-03-20
- Last updated
- 2019-10-22
- Results posted
- 2019-10-22
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00866333. Inclusion in this directory is not an endorsement.